Search
Influenza A virus A/Switzerland/9715293/2013 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB11035ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen
go.drugbank.com/drugs/DB11037ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11040ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11041ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11042ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11046ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Revakinagene taroretcel
go.drugbank.com/drugs/DB05344ApprovedInvestigationalRevakinagene taroretcel is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). It is an allogeneic encapsulated cell-based gene therapy that contains 200,000...
Pomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Eplerenone
go.drugbank.com/drugs/DB00700ApprovedInvestigationalEplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone ...
Etorphine
go.drugbank.com/drugs/DB01497ExperimentalIllicitVet approvedIn certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes.